Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scroll down to companies mentioned:
Annual Forecasts to 2010 for the World's Genetic Testing Market
09/04/2006 01:00:06 PM EDT
Business Wire
DUBLIN, Ireland--(BUSINESS WIRE)--Sept. 4, 2006--Research and Markets (http://www.researchandmarkets.com/reports/c41575) has announced the addition of Genetic Testing - Global Strategic Business Report to their offering.
This report analyzes the worldwide markets for Genetic Testing in Millions of US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 74 companies including many key and niche players worldwide such as Abbott Laboratories, Vysis, AutoGenomics, Inc., BioRad Laboratories, Bioscientia, Celera Diagnostics, Genzyme Genetics, Orchid Cellmark, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Roche Diagnostics, Corp., and Sciona Ltd.
Topics Covered
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
1. Overview
2. Product Overview
3. Advances in the Field of Research
4. Technological Developments
5. Update on the Regulatory Front
6. Product Launches
7. Recent Industry Activity
8. Focus on Select Global Players
9. Global Market Perspective
II. MARKET
1. The United States
2. Canada
3. Japan
4. Europe
5. Rest of World
III. COMPETITION
Companies Mentioned
Abbott Laboratories (USA) - Affiliated Genetics, Inc (USA) - Affymetrix, Inc (USA) - American Genetics, Inc (USA) - Applied Biosystems Group (USA) - Autogenomics, Inc (USA) - Autoimmune Technologies LLC (USA) - Becton, Dickinson & Company (USA) - Biogenetic Services, Inc (USA) - Bio-Rad Laboratories, Inc (USA) - Bioscientia (Germany) - Biotage AB (Sweden) - BRT Laboratories, Inc (USA) - Celera Diagnostics (USA) - Columbia Laboratory Services (USA) - Digene Corporation (USA) - DNA Diagnostics Center (USA) - DNAPrint Genomics, Inc (USA) - Elan Corporation PLC (Ireland) - Fujirebio Diagnostics, Inc (USA) - Genaissance Pharmaceuticals, Inc (USA) - Genecare Medical Genetics Center (USA) - Genedx, Inc (USA) - Genelex Corporation (USA) - Genetest Corporation (USA) - Genetic Profiles Laboratory (USA) - Genetic Technologies, Inc (USA) - Genetica DNA Laboratories, Inc (USA) - Genetics & IVF Institute (USA) - Genetree DNA Testing Center (USA) - Genex Diagnostics Swabtest (USA) - Genomic Health, Inc (USA) - Genova Diagnostics (USA) - Gentra Systems, Inc (USA) - Genzyme Genetics (USA) - Great Lakes Genetics, SC (USA) - Gribbles Group Ltd (Australia) - Healthcheck USA (USA) - ID Labs Biotechnology (Canada) - Identigene (USA) - Identity Genetics, Inc (USA) - IMGM Laboratories (Germany) - Independent Forensics (USA) - Innogenetics NV (Belgium) - Intergenetics, Inc (USA) - Interleukin Genetics, Inc (USA) - Investigen, Inc (USA) - Invitrogen Corporation (USA) - Kimball Genetics, Inc (USA) - Laboratory Corporation Of America Holdings (USA) - Lark Technologies, Inc (USA) - London Biosciences Corporation (UK) - MDS Diagnostic Services (Canada) - Myriad Genetics, Inc (USA) - Nanogen, Inc (USA) - Orchid Cellmark (USA) - Osmetech, Inc Critical Care Division (USA) - Panomics, Inc (USA) - Paragon Genetics(TM) (USA) - Pediatrix Screening (USA) - PerkinElmer, Inc (USA) - Proactive Genetics, Inc (USA) - PRO-DNA Diagnostic (Canada) - Qiagen NV (The Netherlands) - Quest Diagnostics, Inc (USA) - Reliagene Technologies, Inc (USA) - Roche Diagnostics (Switzerland) - Sciona, Inc (USA) - Sequenom, Inc (USA) - St Josephs DNA Diagnostic Laboratories (USA) - Tepnel Life Sciences PLC (UK) - Third Wave Technologies, Inc (USA) - TM Bioscience Corporation (Canada) - Xtrana, Inc (USA
Ann
Scroll down and you will see DNAP listed:
http://www.hoovers.com/free/co/news/detail.xhtml?ID=44998&ArticleID=20060904290.2_6010000f3a96da...
Ann
"With 381.32 million shares outstanding and 3,584 shares declared short as of August 2006, there is no longer a failure to deliver in shares of DNAG."
Ann
DNAG off Sho list:
http://www.stockhouse.com/news/news.asp?tick=DNAG&newsid=3888807
Ann
From today's PR:
"It is important to protect the company's technologies and the revenue that can be derived from them," stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Our proprietary methods for marking gene sequences are especially important, because they are the key to developing theranostic drugs."
The patent provides legal protection for DNAPrint's status as one of few companies currently capable of performing objective, assumption-free haplotype analysis of DNA strands.
DNAPrint Genomics currently holds two other patents and has several others pending or in the hands of patent counsel.
Ann
Disregard first wire re: stockholder's meeting post - lol
Ann
June 22 stockholder's meeting:
http://www.sec.gov/Archives/edgar/data/1127354/000123174206000376/dnagdef14c.txt
Ann
9car:
Your reply & input is much appreciated
Ann
Thank you, 'retired'. Appreciate it.
Ann
From the filing - can anyone tell me what this basically means or what the filing generally relates to?
"Approximate date of proposed sale to the public: as soon as practicable after this Registration Statement becomes effective."
Ann
stockboy:
OT:
"I think this "STOCK" is a joke"
Stock Who? - referring to yourself? - lol
Ann
"DNAPrint Genomics currently holds two patents and has several others pending or in the hands of patent counsel."
More later...Ann
"The recent patent provides legal protection for DNAPrint's status as one of a very few companies currently capable of performing objective, assumption-free haplotype analyses. DNAPrint is also the only company currently using Ancestry Informative Markers (AIMs) and has patents pending in this area as well. Because of limitations with traditional genome screening methods and the complex genetic characteristics of modern populations, AIMS are integral to the development of DNA tests for the inference of genetic ancestry based on phenotypes, including identifying certain physical characteristics, or an individual's predisposition to respond to certain drugs."
Ann
Tony Frudakis noted:
http://www.advfn.com/news_dnaprint-notches-another-publication_8315608.html
Ann
DNAP release on upgrade of DNAWITNESS/Retinome:
http://www.marketwire.com/mw/release_html_b1?release_id=152528
Ann
ann441j
"I do not mean to offend you regarding the optimism which you and Virgil are reading in the latest effort by the management of this company...
________________________________________________________
Dr. Fru:
I appreciate your taking the time...(I think?)
As you know, it is never my intent to participate in defensive or serious discussions on this board. I leave that to the more knowledge-based debators. I judge myself only to be a common-sense intellect and I mostly post relative & pertinent information that I feel might be of interest to the investors who will unlimately form their own opinions. So, just a reminder - Dr."24/7" Fru - You have your agenda (hmmm?)...and I have mine.
Ann
Virgil:
I agree w/your assessment.
Ann
Desig. Marketing provides:
"MARKET EXPOSURE:
The ability tell your story to thousands of new investors over the phone, and to place your story in front of thousands, even millions, of new investors, is an important component of any successful Designated Marketing campaign. Designated Marketing has identified several fundamental exposure systems that have proven to be quite effective, and are now standard components of our I.R. campaign"
Ann
Designated Marketing web site:
http://www.designatedmarketing.com/services.html
Ann
Thanks, 9car -
Ann
I apologize for the numerous posts for those who are already familiarized with the subject of DNAP's participation in these most current projects. The main objective is for new investors' perusal. However, if you'd rather I post old Russian recipes, I can also readily comply - lol
Ann
The source:
http://www.genetree.com/other/Forensics.php
Ann
Thanks to the highly rated CSI series on television, many of you are familiar with the use of DNA at crime scenes. GeneTree brings state of the art DNA Testing services to crime labs, district attorneys, private investigators and other legal professionals who look to DNA for answers and evidence. DNA Detective Testing
GeneTree brings state-of-the-art DNA forensic testing services to crime labs, district attorneys, private investigators and other professional looking to DNA for answers.
A DNAP distributor.
Ann
GeneTree - DNAP distributor:
WHOLE DNA
Most DNA tests look at either the Y chromosome (father's line) or mtDNA (mother's line). An autosomal test samples your entire gene, containing the sequences inherited down the generations from ALL your ancestors. AncestryByDNA 2.5 is the latest and most reliable version of DNAPrint, a test that gives you the ethnic profile of your entire gene according to a set of Ancestry Informative Markers (AIMs). As with our other tests, you receive a sample collection kit by overnight courier containing a cheek swab and send your sample back to our lab. We provide you with an evaluation and DNAPrint from our partner GeneTree listing your whole gene's estimated mix of 1) Indo-European, 2) African, 3) Native American, and 4) East Asian origins, also a CD-ROM with your report, certificate, and a map of origins. Please allow 6-8 weeks for processing of your DNAPrint test.
Ann
Now this is DNAP Ancestry testing: - (more - later)
http://www.genetree.com/ancestral/ancestryByDna.php
Ann
DNAP/Spain interaction:
"Successful in engineering and housing Spain’s largest databank of DNA samples, NeoCodex has created a nationwide cooperative of hospital systems, working together to build a fully-annotated network of samples from common disease states present within the uniquely homogenous population of Spain."
Ann
Application of Patented Technologies:
http://www.neocodex.com/Cap3.aspx
Ann
8/22/06 DNAP News Release:
(A re-read)
DNAPrint alliance targets ovarian cancer treatments
Tampa Bay Business Journal - August 22, 2006
DNAPrint Genomics Inc. has a strategic alliance with a Spanish firm to provide DNA sampling for ongoing research into theranostic (drug/test combinations) test and drug treatments for ovarian cancer.
Under the terms of the agreement, business units in Spain and in the United States of NeoCodex Inc. will gather DNA samples that will be tested by DNAPrint Genomics for research into the effectiveness of certain treatments for ovarian cancer. Specifically, it will involve combined treatments of Taxotere, Taxol, Carboplatin and Cisplatin.
No financial terms were disclosed.
NeoCodex SL is based in Sevilla, Spain and is a biomedical and genomic research provider. It is focused on understanding the molecular and genetic basis of human disease, and on employing novel methodologies for the continued improvement of current genetic analysis techniques, a release said.
DNAPrint Genomics Inc. in Sarasota is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals Inc. is a subsidiary, and develops diagnostic tests and theranostic products using the proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology.
Ann
Extremely interesting to look back to DNAP's 1st Newsletter to the shareholders:
"We have constructed a library of SNP maps, showing where, in genes, individual human beings differ from one another. Our maps are by far the best in the world. Due mainly to our proprietary (and patent pending) protocols, our SNP maps are deeper and more detailed than those held publicly (NCBI) or privately (such as at Celera, Affymetrix, Incyte, Human Genome Sciences and even Gennaissance). Furthermore, our maps cover the entire length of the gene in the genome. The maps being constructed by others are focused at the ends. This is a crucial point because the depth and breadth of the maps are important! You can think of them as “treasure maps” - the more detailed and accurate the map, the better your chance of finding the treasure. As an investor in DNAPrint genomics, you should feel proud that you own a piece of the most comprehensive and valuable pharmaco-relevant SNP library on the planet.
We continue to write code for the high-throughput and automated mining of complex genetic pattern from our data. When I speak at meetings with executives of other private and publicly held companies, I am continually amazed at how little effort they are putting into genetics IT and discovery. The reason for this is, that it’s hard, and hard things tend to get done last. Thus, any company that builds a system to solve genetics problems on a genomics scale is worth its’ weight in gold. At the close of year one, DNAPrint is about half way to having our informatics platform for solving these problems completed. We have developed 8 different software components of this platform, and filed patents covering their composition and use. For example, we have filed on a proprietary cladistics-based, geometric modeling scheme for identifying epistatic and dominance components of quantitative genetic variance. To our knowledge, there are no other programs like this anywhere in the world.
We have assembled a world-class laboratory with state-of-the-art equipment. We are sequencing well over 1 Million bases per week and scoring about 2,000 genotypes per day.
We have assembled what may well be the most extensive, detailed and valuable pharmacogenomics specimen databank in the world. We have had the foresight to collect multi-drug consent from our donors, and to log everything in their patient files into our database. No other company does this. Since most of our patients are on multiple medications and since we genotype every person at every pharmaco-relevant marker (unlike our competition), we have the ability to perform multiple and simultaneous pharmacogenomics projects. Please appreciate what this means. Using this type of “master” databank, DNAPrint will be able to outrun its competition in getting pharmacogenomics products discovered and developed to market.
Ann
bag:
OT:
"What do you feed your seeing-eye dog?"
Is fr-og food a good guess? - lol
Hope all have a good Labor Day holiday.
Ann
Discussion of 2nd quarter results:
http://www.genengnews.com/news/bnitem.aspx?name=4764983
Ann
DNAPrint Pharmaceuticals Completes The Development Of An Analytical Method That Will Be Used For The Development Of PT-401
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its subsidiary, DNAPrint Pharmaceuticals, Inc., has completed the development of the so-called "Western blot" method, an analytical procedure that identifies a protein according to its interaction with a specific antibody, a significant step in the development of its PT-401-based proprietary drug to treat anemia.
(See Story from BioSpace.com) (07/31/2006)
Ann
DNAPrint Pharmaceuticals Completes The Development Of A Second Assay For Its Anemia Drug
DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that KBI BioPharma, Inc., has completed and validated a second analytical method for PT-401, based on SDS-PAGE, a well established separation technique that will be used for in-process analysis, release and stability testing for its PT-401 anemia drug, which is being developed by its subsidiary, DNAPrint Pharmaceuticals, Inc.
(See Story from BioSpace.com) (08/04/2006)
Ann
Jeever:
(Hysterical over-dramatization, between two women - voice-overs, audio run on "The Larry Elder," K-ABC radio talk show):
___________________________________________________________
"No, I'm my sister!...You're my mother!..."
"You're my sister...I'm my daughter!"
___________________________________________________________
You might find it all confusing/amusing, but so do we at your unpredictable predictions. - lol
Ann
What's up w/that?
Ann
Jeever:
What's the movie film clip promo all about?
Didn't play it to the end...
Ann
From RB:
Direct access to Quarterly Financials & Interview:
http://brighttalk.com/event/DNAPrint/e2ef524fbf-97-intro
http://www.mn1.com/members/modules.php?name=Downloads&d_op=getit&lid=316
Look at the numbers, dilution is drying up, revenue increasing and share price is stable.
Projected outstanding shares and share price in next 10Q report is 405,767,754 outstanding shares and share price of $0.01616.
Although my opinion this price is seriously undervalued, DNAPrint Genomics is working on a major Genotyping deal which will result in an increased revenue stream, as well the increase in genetic ancestry & genotyping deals will increase. As their focus on forensics is increasing I anticipate forensics will take off again resulting in an increased revenue stream.
I do not have projections of next quarterly financials, however I anticipate they will be above 30% revenue increase upon the 65% of Q2.
Ann
DNAP News - Financial Update:
http://money.aol.com/news/articles/_a/dnaprint-genomics-financial-update-and/n20060828073009990005
Ann